$NUVB News

RBC Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $19

Truist Securities Maintains Buy on Nuvation Bio, Raises Price Target to $13

Nuvation Bio Intends To Offer $200M Aggregate Principal Amount Of Convertible Senior Notes Due In 2032

Nuvation Bio: David Hung's Latest Venture Looks Undervalued At Current Level

Nuvation Bio: Buy The Ibtrozi Launch (Rating Upgrade)

Nuvation Bio to Present at the Jefferies Global Healthcare Conference

Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting

Nuvation Bio To Showcase New Outcomes Data From Its Pivotal TRUST-II Trial Of IBTROZI In Participants With Advanced ROS1-Positive Non-Small Cell Lung Cancer

Nuvation Bio Inc. (NUVB) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Nuvation Bio Inc. (NUVB) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference Transcript

Nuvation Bio Inc. (NUVB) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Is Nuvation Bio (NUVB) the Best Penny Stock to Buy Before It Explodes?

Nuvation Bio Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer

Nuvation Bio to Participate in Upcoming Investor Conferences

RBC Capital Reiterates Outperform on Nuvation Bio, Maintains $20 Price Target

Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target

HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $17 Price Target

Nuvation Bio Q1 Earnings Call Highlights

Nuvation Bio Inc. Q1 2026 Earnings Call Summary